

P & T Committee Policy for Public Comment

- A. Public comment during the P & T Committee Meeting is limited to representatives from the pharmaceutical industry and is not open to the general public, representatives of advocacy/special interest groups or members of academic organizations unless such individual is designated to speak on behalf of the industry by the industry.
- B. Registration prior to the P & T Committee Meeting is required. Speakers may register 1 month in advance of the meeting date.
- C. Content is limited to drugs relevant to the drug classes on the agenda to be discussed during the meeting.
- D. Speakers must sign in at least ten (10) minutes prior to the start of the meeting; otherwise the speaker will not be permitted to speak during the public comment period.
- E. Presentations
 - (1) The Chair will recognize the speakers according to the order in which they are listed on the sign in sheet.
 - (2) Speakers may only provide oral presentations; no visual or audio aids may be used.
 - (3) Per the request of the Committee, no written documents or handouts are to be provided to Committee members prior to and/or during meeting.
 - (4) Speakers shall limit their presentation to three (3) minutes per drug/per class/per manufacturer.
 - (5) The presentation should focus on the clinical advantages of the particular product and should refrain from criticizing the products from other competitors.
- F. No questions or comments from the audience will be entertained unless approval is granted by two-thirds of the members present at the meeting.
- G. The Committee reserves the right to suspend or eliminate the period for public comment if the privilege becomes abused or is deemed to be non-productive.